Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice

Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Sharon C. Cunningham, Alexandra Sharland, Ian E. Alexander, Peter W. Angus, Chandana B. Herath – 10 October 2019 – There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a disease that commonly results in liver failure. Angiotensin (Ang) II of the renin Ang system (RAS) is a potent profibrotic peptide, and Ang converting enzyme 2 (ACE2) of the alternate RAS breaks down Ang II to antifibrotic peptide Ang‐(1‐7).

Nontranscriptional Activity of Interferon Regulatory Factor 3 Protects Mice From High‐Fat Diet‐Induced Liver Injury

Carlos Sanz‐Garcia, Megan R. McMullen, Saurabh Chattopadhyay, Sanjoy Roychowdhury, Ganes Sen, Laura E. Nagy – 10 October 2019 – Interferon regulatory factor 3 (IRF3) has both transcriptional and nontranscriptional functions. Transcriptional activity is dependent on serine phosphorylation of IRF3, while transcription‐independent IRF3‐mediated apoptosis requires ubiquitination. IRF3 also binds to inhibitor of nuclear factor kappa B kinase (IKKβ) in the cytosol, restricting nuclear translocation of p65.

qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

Feng Liu, George Boon‐Bee Goh, Dina Tiniakos, Aileen Wee, Wei‐Qiang Leow, Jing‐Min Zhao, Hui‐Ying Rao, Xiao‐Xiao Wang, Qin Wang, Wei‐Keat Wan, Kiat‐Hon Lim, Manuel Romero‐Gomez, Salvatore Petta, Elisabetta Bugianesi, Chee‐Kiat Tan, Stephen A. Harrison, Quentin M. Anstee, Pik‐Eu Jason Chang, Lai Wei – 10 October 2019

LiverLearning®: 2019 Webinar: Systematic Screening for NAFLD-Related Advanced Fibrosis in Patient with Type 2 Diabetes, Where Do We Stand? WEBINAR

The systematic screening for NAFLD is currently not recommended by the AASLD practice guidelines although the presence of type 2 diabetes is a known risk factor for the progression of NAFLD towards NASH and advanced fibrosis. This webinar will discuss the pros and cons for the systematic screening of NAFLD-related advanced fibrosis in patient with type 2 diabetes.

Subscribe to